×
About 500 results

ALLMedicine™ Juvenile Myelomonocytic Leukemia Center

Research & Reviews  189 results

Myelodysplastic Syndromes Staging
https://emedicine.medscape.com/article/2007806-overview

May 4th, 2022 - WHO Classification and IPSS of Myelodysplastic Syndromes The 2016 World Health Organization (WHO) classification of myelodysplastic syndromes (MDS), [1] as well as the International Prognostic Scoring System (IPSS), are provided below. [2] The 201...

Inhibition of BTK and PI3Kδ impairs the development of human JMML stem and progenitor c...
https://doi.org/10.1016/j.ymthe.2022.04.009
Molecular Therapy : the Journal of the American Society O... Ramdas B, Yuen LD et. al.

Apr 22nd, 2022 - Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloproliferative neoplasia that lacks effective targeted chemotherapies. Clinically, JMML manifests as monocytic leukocytosis, splenomegaly with consequential thrombocytopenia. Most common...

Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
https://clinicaltrials.gov/ct2/show/NCT00167219

Apr 22nd, 2022 - Prior to transplantation, subjects will receive BUSULFAN via the central venous line, six times a day for four days, CYCLOPHOSPHAMIDE via the central venous line once a day for two days, and MELPHALAN via the central venous line for one day. Busul...

Therapy-related myeloid neoplasms resembling juvenile myelomonocytic leukemia: a case s...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957526
Pediatric Blood & Cancer; Wintering A, Smith S et. al.

Dec 24th, 2021 - Therapy-related myeloid neoplasms (t-MN) are a distinct subgroup of myeloid malignancies with a poor prognosis that include cases of therapy-related myelodysplastic syndrome (t-MDS), therapy-related myeloproliferative neoplasms (t-MPN) and therapy...

see more →

Clinicaltrials.gov  6 results

Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
https://clinicaltrials.gov/ct2/show/NCT00167219

Apr 22nd, 2022 - Prior to transplantation, subjects will receive BUSULFAN via the central venous line, six times a day for four days, CYCLOPHOSPHAMIDE via the central venous line once a day for two days, and MELPHALAN via the central venous line for one day. Busul...

Azacitidine and Homoharringtonine in JMML
https://clinicaltrials.gov/ct2/show/NCT04505995

Aug 10th, 2020 - Juvenile myelomonocytic leukemia (JMML) has a poor prognosis in general, with hematopoietic stem cell transplant (HSCT) remaining the standard of care for cure. Azacitidine and homoharringtonine, which exhibited a anticancer mechanism and has been...

Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)
https://clinicaltrials.gov/ct2/show/NCT02447666

Jul 11th, 2019 - Study Population Pediatric subjects aged 1 month to less than 18 years of age with newly diagnosed conditions of advanced myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML). Length of Study The enrollment period will last fo...

Modified Post-Transplant Cyclophosphamide Regimen for Children With Juvenile Myelomonocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT03687463

Oct 2nd, 2018 - Hematopoietic stem cell transplantation (HSCT) is the only curative option for most of juvenile myelomonocytic leukemia (JMML). However, persistent disease statute and relapse after HSCT severely influence the long-term overall survival (OS). Rese...

Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome
https://clinicaltrials.gov/ct2/show/NCT00047268

Sep 17th, 2013 - OBJECTIVES: Determine, by a standard approach, the frequency of different FAB subtypes in children with primary myelodysplastic syndromes. Determine the frequency of cytogenetic and molecular abnormalities in these patients. Determine the survival...

see more →

News  4 results

Genomic Era Reaches Pediatric Oncology
https://www.onclive.com/view/genomic-era-reaches-pediatric-oncology

Dec 5th, 2020 - Rajen Mody, MBBS The relative rarity of pediatric cancers has hampered the work of uncovering their causes and developing new therapies, but efforts to expand the use of genomic and biomarker testing are beginning to provide new options for child...

Pediatric Dermatology Consult - April 2017
https://www.mdedge.com/pediatrics/article/136266/pediatric-dermatology-consult-april-2017

Apr 21st, 2017 - BY JEREMY UDKOFF AND CATALINA MATIZ, MD Juvenile xanthogranuloma (JXG), a non–Langerhans cell histiocytosis, is a common pediatric tumor that most commonly presents either at birth, in infants, or in young children – with the majority of cases occ.

Findings may inform design of new treatments for JMML
https://www.mdedge.com/hematology-oncology/article/187565/leukemia-myelodysplasia-transplantation/findings-may-inform-design-new
HT Staff

Oct 9th, 2015 - Colony of iPSCs Image from the Salk Institute Researchers have used induced pluripotent stem cells (iPSCs) to model juvenile myelomonocytic leukemia (JMML) and gain new insight into the disease. The team noted that somatic PTPN11 mutations are kno.

New Finding May Improve Diagnosis of Juvenile Leukemia
https://www.medscape.com/viewarticle/581586

Oct 6th, 2008 - October 6, 2008 — The diagnostic utility of flow cytometry has significantly improved over the past decade, and these advances have made it possible to simultaneously measure the cell type and signaling abnormalities that occur as a result of gene...

see more →

Patient Education  1 results see all →